Smith Graham & Co Investment Advisors LP Stake in Boston Beer Co (SAM) Has Lifted as Shares Declined; As Amicus Therapeutics (FOLD) Stock Rose, Redmile Group Cut Position

January 13, 2018 - By Peter Kolinski

Jeremy Green decreased its stake in Amicus Therapeutics Inc (FOLD) by 8.56% based on its latest 2017Q3 regulatory filing with the SEC. Redmile Group Llc sold 1.03M shares as the company’s stock rose 23.92% with the market. The hedge fund run by Jeremy Green held 11.01 million shares of the health care company at the end of 2017Q3, valued at $166.07 million, down from 12.04M at the end of the previous reported quarter. Redmile Group Llc who had been investing in Amicus Therapeutics Inc for a number of months, seems to be less bullish one the $2.61B market cap company. The stock decreased 0.95% or $0.15 during the last trading session, reaching $15.72. About 2.82 million shares traded or 23.44% up from the average. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since January 13, 2017 and is uptrending. It has underperformed by 4.25% the S&P500.

Smith Graham & Co Investment Advisors Lp increased its stake in Boston Beer Co Inc (SAM) by 14.54% based on its latest 2017Q3 regulatory filing with the SEC. Smith Graham & Co Investment Advisors Lp bought 6,870 shares as the company’s stock declined 15.67% while stock markets rallied. The institutional investor held 54,108 shares of the consumer non-durables company at the end of 2017Q3, valued at $8.45M, up from 47,238 at the end of the previous reported quarter. Smith Graham & Co Investment Advisors Lp who had been investing in Boston Beer Co Inc for a number of months, seems to be bullish on the $2.22 billion market cap company. The stock decreased 1.12% or $2.15 during the last trading session, reaching $190.5. About 134,377 shares traded. The Boston Beer Company, Inc. (NYSE:SAM) has declined 3.11% since January 13, 2017 and is downtrending. It has underperformed by 19.81% the S&P500.

Since October 31, 2017, it had 0 buys, and 10 sales for $10.35 million activity. 439 shares were sold by POTTER JONATHAN N., worth $75,464. $1.53M worth of The Boston Beer Company, Inc. (NYSE:SAM) shares were sold by Geist John C. Another trade for 64 shares valued at $12,090 was made by HEATH TARA L. on Tuesday, January 2. ROPER MARTIN F sold $1.93M worth of stock. Fisher Cheryl sold $17,569 worth of stock or 93 shares. Shares for $186,750 were sold by Grinnell David L..

Investors sentiment decreased to 1.15 in 2017 Q3. Its down 0.04, from 1.19 in 2017Q2. It fall, as 19 investors sold SAM shares while 69 reduced holdings. 43 funds opened positions while 58 raised stakes. 8.75 million shares or 3.77% more from 8.43 million shares in 2017Q2 were reported. Pacad owns 1,200 shares or 0.04% of their US portfolio. State Treasurer State Of Michigan holds 3,400 shares or 0% of its portfolio. Tower Research Ltd (Trc) accumulated 1,139 shares. Meeder Asset Mngmt holds 0.09% or 5,126 shares. 283 are held by Huntington Natl Bank. The New York-based Laurion Capital Mgmt Limited Partnership has invested 0% in The Boston Beer Company, Inc. (NYSE:SAM). Tudor Et Al holds 5,439 shares. Gabelli Funds Ltd Llc invested in 25,000 shares. Jpmorgan Chase And holds 0% or 118,251 shares. Aperio Gru Ltd stated it has 5,392 shares or 0% of all its holdings. Thrivent Financial For Lutherans owns 1,910 shares. Wolverine Asset Mgmt Ltd Liability has 532 shares for 0% of their portfolio. Bnp Paribas Arbitrage holds 0% or 4,935 shares in its portfolio. Glenmede Tru Company Na has 0% invested in The Boston Beer Company, Inc. (NYSE:SAM). Arizona State Retirement Sys owns 0.01% invested in The Boston Beer Company, Inc. (NYSE:SAM) for 5,098 shares.

Among 15 analysts covering Boston Beer Co (NYSE:SAM), 1 have Buy rating, 4 Sell and 10 Hold. Therefore 7% are positive. Boston Beer Co had 54 analyst reports since July 28, 2015 according to SRatingsIntel. The company was maintained on Thursday, January 4 by Jefferies. On Thursday, July 27 the stock rating was maintained by Jefferies with “Hold”. On Thursday, May 19 the stock rating was upgraded by Berenberg to “Hold”. RBC Capital Markets maintained The Boston Beer Company, Inc. (NYSE:SAM) on Thursday, September 14 with “Hold” rating. The stock has “Hold” rating by RBC Capital Markets on Friday, June 30. On Monday, June 12 the stock rating was maintained by Cowen & Co with “Sell”. As per Monday, January 11, the company rating was downgraded by Nomura. As per Monday, January 8, the company rating was maintained by Cowen & Co. Citigroup maintained The Boston Beer Company, Inc. (NYSE:SAM) on Monday, October 30 with “Neutral” rating. The firm earned “Hold” rating on Friday, January 8 by Jefferies.

Smith Graham & Co Investment Advisors Lp, which manages about $5.56 billion and $953.92 million US Long portfolio, decreased its stake in Ultra Clean Hldgs (NASDAQ:UCTT) by 273,212 shares to 602,752 shares, valued at $18.46 million in 2017Q3, according to the filing. It also reduced its holding in Green Dot Corp (NYSE:GDOT) by 48,370 shares in the quarter, leaving it with 360,253 shares, and cut its stake in Ralph Lauren Corporation (NYSE:RL).

Among 9 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Amicus Therapeutics had 20 analyst reports since August 18, 2015 according to SRatingsIntel. Leerink Swann maintained the shares of FOLD in report on Monday, October 5 with “Outperform” rating. As per Thursday, April 14, the company rating was initiated by Robert W. Baird. The company was maintained on Sunday, June 25 by Cowen & Co. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Neutral” rating by Goldman Sachs on Wednesday, March 30. The rating was downgraded by Zacks to “Buy” on Tuesday, August 18. The firm has “Buy” rating by Janney Capital given on Tuesday, March 8. The firm has “Buy” rating by Bank of America given on Wednesday, May 18. The rating was maintained by Cowen & Co with “Buy” on Sunday, August 13. Cowen & Co maintained the stock with “Buy” rating in Tuesday, September 1 report. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has “Buy” rating given on Monday, August 7 by Cowen & Co.

Since October 12, 2017, it had 0 insider purchases, and 14 insider sales for $10.19 million activity. On Tuesday, January 2 RAAB MICHAEL sold $140,490 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 9,366 shares. Barth Jay sold 5,000 shares worth $73,559. Shares for $1.06M were sold by Crowley John F on Tuesday, October 17. Shares for $117,723 were sold by Quimi Daphne on Tuesday, January 2. $570,132 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) was sold by Baird William D III on Thursday, October 12. 20,000 shares were sold by HAYDEN DONALD J JR, worth $300,002 on Tuesday, January 2.

Analysts await Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report earnings on March, 7. They expect $-0.30 earnings per share, up 6.25% or $0.02 from last year’s $-0.32 per share. After $-0.41 actual earnings per share reported by Amicus Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -26.83% EPS growth.

Investors sentiment increased to 2.33 in Q3 2017. Its up 1.10, from 1.23 in 2017Q2. It is positive, as 16 investors sold FOLD shares while 32 reduced holdings. 52 funds opened positions while 60 raised stakes. 192.70 million shares or 14.18% more from 168.77 million shares in 2017Q2 were reported. Balyasny Asset Ltd Liability Corp owns 12,900 shares. Commonwealth Equity Svcs reported 0% stake. Wells Fargo Mn invested in 0% or 197,804 shares. 7,215 are held by Fortaleza Asset Mngmt. Voloridge Investment Ltd Liability Co owns 362,440 shares. Washington-based Parametric Port Ltd Limited Liability Company has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Acuta Limited Co holds 300,000 shares. Axa reported 0.03% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). American Int Incorporated reported 109,628 shares or 0.01% of all its holdings. Parallax Volatility Advisers Lp stated it has 132,723 shares or 0% of all its holdings. Emory University, Georgia-based fund reported 132,479 shares. Aperio Grp Inc Limited Liability Com holds 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 15,326 shares. Chicago Equity Prns Lc has invested 0.02% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Citadel Advsrs Ltd owns 1.88 million shares for 0.02% of their portfolio. Lpl Fincl Ltd Company reported 15,465 shares or 0% of all its holdings.

Redmile Group Llc, which manages about $1.27 billion and $2.03B US Long portfolio, upped its stake in Glycomimetics Inc (NASDAQ:GLYC) by 614,468 shares to 1.21 million shares, valued at $16.99 million in 2017Q3, according to the filing. It also increased its holding in Invitae Corp by 1.30M shares in the quarter, for a total of 2.11 million shares, and has risen its stake in Irhythm Technologies Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>